CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To understand and address, through clinical and translational research, the disease burden associated with genitourinary malignancies in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to genitourinary malignancies.
- To update, review, and discuss recent results of clinical studies conducted by or in collaboration with NCIC Clinical Trials Group.
- To provide mentoring opportunities for investigators new to clinical trial research.
- To understand and apply new clinical trial methodologies in the field of clinical research related to genitourinary malignancies.

10:00 am  WELCOME  K. Chi/N. Fleshner

NCIC CTG Lead OPEN TRIALS

10:05 am  IND.209 Reolysin in combination with docetaxel and prednisone or docetaxel and prednisone alone in metastatic CRPC  B. Eigl

10:15 am  BL.12 Phase II Randomized trial of Nab-Paclitaxel vs. Paclitaxel in Second Line Metastatic Urothelial Carcinoma  K. Sridhar

10:25 am  PR.15 HDR Brachytherapy in Intermediate Risk CaP  E. Vigneault/ A. Loblaw

NCIC CTG InterGroup OPEN TRIALS

10:35 am  BLC.1/SWOG S1011 Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed at the Time Of Radical Cystectomy For Muscle Invasive Urothelial Cancer  W. Kassouf

continued on next page …
10:45 am PR.13/RADICALS/MRC PR.10
Radiotherapy and Androgen Deprivation In Combination After Local Surgery.

C. Catton

10:55 am PRC.3/CALGB 90203 Neoadjuvant Docetaxel plus Androgen Deprivation prior to RP v.s. RP only
K.Chi
on behalf of M. Gleave/F. Saad

11:05 am PRC.4/Alliance A031201 Phase III Enzalutamide + Abiraterone in castration resistant metastatic prostate cancer
K.Chi

11:15 am PR.17/ANZUP - ENZAMET Phase III testosterone suppression with or without Enzalutamide in first line metastatic prostate cancer
S. North

NCIC CTG InterGroup CLOSED TRIALS

11:25 am BL.8/EORTC 30994 Randomized phase III comparing immediate vs. deferred chemotherapy after radical cystectomy in patients with pT3-pT4, and/or N+M0 transitional cell carcinoma (TCC) of the bladder
K.Chi
on behalf of L. Wood//F. Saad

11:30 am REC.2/ECOG E2805 Sunitinib/placebo vs. Sorafenib/placebo vs. placebo in resected RCC
M. Jewett/ L. Wood

11:35 am OPEN CUOG/CURC TRIALS

Affinity
Synergy
IAS + Dutasteride
EORTC Cytoreductive
FIT
ProstVac
Hypothermia RCC

K.Chi
K.Chi
L. Klotz
M. Jewett
L. Klotz
N. Fleshner
I. Cagiannos

12:00 pm LUNCH

1:30 pm Plenary Presentation: Designing trials to improve the care of patients with advanced prostate cancer.
J. de Bono
Dr. de Bono biography

2:10 pm DOG REPORTS/NEW PROPOSALS/GU DIRECTIONS

Localized Prostate Cancer
Advanced Prostate Cancer
Bladder
Kidney
Testes
Correlative Studies

A. Loblaw/N. Fleshner
K. Chi
S. North/W. Kassouf/A. So
A. Kapoor
P. Chung
R. Bristow

3:45 pm Meeting Adjourned

3:45 PM – 4:15 PM EXECUTIVE COMMITTEE MEETING – CLOSED